Back HCV Treatment

Harvoni Coformulation Approved in Europe for Hepatitis C Genotypes 1 & 4

Gilead Sciences' Harvoni, a once-daily fixed-dose coformulation containing the nucleotide HCV polymerase inhibitor sofosbuvir and the NS5A replication complex inhibitor ledipasvir, has been approved by the European Commission for the treatment of people with hepatitis C genotypes 1 and 4, the company announced this week.


Read more: